| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 08/01/2002 | US20020103239 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity |
| 08/01/2002 | US20020103235 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 08/01/2002 | US20020103234 Heterocycl-containing carboxylic acid derivative and drug containing the same |
| 08/01/2002 | US20020103229 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 08/01/2002 | US20020103227 Nitric oxide synthase inhibitors such as 6(4'-(4-phenethyl-piperazin-1-ylmethyl)-biphenyl-4-yl)-pyridin-2-ylamine for treatment and prevention of central nervous system disorders |
| 08/01/2002 | US20020103217 Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids |
| 08/01/2002 | US20020103213 Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis |
| 08/01/2002 | US20020103212 Pharmaceutical compositions containing anti-fas antibody |
| 08/01/2002 | US20020103211 For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders |
| 08/01/2002 | US20020103190 Azo amino acids derivatives |
| 08/01/2002 | US20020103182 Improving elasticity or reducing wrinkles of a skin, for example; advanced glycosylation endproducts" or AGEs |
| 08/01/2002 | US20020103180 Methods, compositions and articles for reducing or preventing the effects of inflammation |
| 08/01/2002 | US20020103172 Vitamin d3 derivatives |
| 08/01/2002 | US20020103166 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders |
| 08/01/2002 | US20020103159 Chitosan and a polysaccharide selected from heparin, heparan sulphate manufacture lactating animals, particularly cows; prophylactic or wound healing treatment for mastitis; bacterial barrier; bacteriostats |
| 08/01/2002 | US20020103123 Administering coumpounds such as aromatic alkyl diamine derivatives as Y5 receptor agonist or antagonist to increase or decrease food consumption |
| 08/01/2002 | US20020103111 Comprising peptide sequences which mimic the conserved amino acid motif LDTSL of MAdCAM-1 and which have groups bonded to the N- and C- termini; treatment of inflammatory bowel disease |
| 08/01/2002 | US20020102733 Drug delivery system; obtain receptive binding particles, incubate with surface and hydrophilic polymer, incubate with release agent, monitor distribution through biological systems |
| 08/01/2002 | US20020102691 Enzymatic polypeptide for use in treatment and prevention of, heart liver and inflammatory disorders |
| 08/01/2002 | US20020102642 Nuclelotide sequences coding preferential protein for use in therapeutic, diagnostic and medical imaging |
| 08/01/2002 | US20020102619 Heparanase specific molecular probes and their use in research and medical applications |
| 08/01/2002 | US20020102609 Antagonists of HMG1 for treating inflammatory conditions |
| 08/01/2002 | US20020102535 Nucleic acid molecules and polypeptides for immune modulation |
| 08/01/2002 | US20020102307 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 08/01/2002 | US20020102302 Stabilized sustained release tramadol formulations |
| 08/01/2002 | US20020102298 Temperature-sensitive liposomal formulation |
| 08/01/2002 | US20020102294 Aerosols comprising nanoparticle drugs |
| 08/01/2002 | US20020102256 Peptide and polypeptide inhibitors of complement C1s |
| 08/01/2002 | US20020100854 Furnace mount and method of installation |
| 08/01/2002 | CA2436139A1 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | CA2435950A1 Use of bicylic amino acids for preventing and treating visceral pain and gastrointestinal disorders |
| 08/01/2002 | CA2435801A1 Styrene derivative and process for preparing the same |
| 08/01/2002 | CA2435647A1 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 08/01/2002 | CA2435418A1 Use of neurotoxic substances in producing a medicament for treating joint pains |
| 08/01/2002 | CA2435409A1 Novel cannabimimetic ligands |
| 08/01/2002 | CA2435124A1 Formulation of boronic acid compounds |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2434558A1 Imidazolyl derivatives as corticotropin releasing factor inhibitors |
| 08/01/2002 | CA2434052A1 Use of rhein for preparing a medicine for treating a high level of il-1 |
| 08/01/2002 | CA2433681A1 Sulfatases and methods of use thereof |
| 08/01/2002 | CA2431904A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | CA2431493A1 Aminoacyl trna synthetases |
| 08/01/2002 | CA2431177A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | CA2429353A1 Lfa-1 antagonist compounds |
| 08/01/2002 | CA2428084A1 Treatment of inflammatory bowel disease using growth factors |
| 08/01/2002 | CA2427647A1 Nucleic acid modification enzymes |
| 08/01/2002 | CA2426102A1 Method of diagnosing and treating cartilaginous disorders |
| 08/01/2002 | CA2425506A1 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 07/31/2002 | EP1227152A1 Bacterial strain and genome of bifidobacterium |
| 07/31/2002 | EP1227098A1 Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents |
| 07/31/2002 | EP1227092A2 Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1227091A2 Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1226821A2 The use of 2,3-alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome |
| 07/31/2002 | EP1226820A1 Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders |
| 07/31/2002 | EP1226441A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies |
| 07/31/2002 | EP1226435A1 Axor35, a g-protein coupled receptor |
| 07/31/2002 | EP1226252A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226251A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226246A1 Polypeptides with expanded primary signalling motifs |
| 07/31/2002 | EP1226245A2 Hybrid adaptor receptors |
| 07/31/2002 | EP1226244A2 Polypeptides with non-natural primary signalling motifs |
| 07/31/2002 | EP1226237A2 Method of identifying inhibitors of cdc25 |
| 07/31/2002 | EP1226173A1 Single-chain antagonist polypeptides |
| 07/31/2002 | EP1226155A2 18-nor-steroids as selectively active estrogens |
| 07/31/2002 | EP1226154A1 Estradiol conjugates and uses thereof |
| 07/31/2002 | EP1226144A1 Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 07/31/2002 | EP1226143A2 Imidazopyridine derivatives used as phosphodiesterase vii inhibitors |
| 07/31/2002 | EP1226141A1 Heterocyclic substituted pyrazolones |
| 07/31/2002 | EP1226137A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 07/31/2002 | EP1226136A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226129A1 Methods and compositions utilizing quinazolinones |
| 07/31/2002 | EP1226126A1 Pyrimidine derivatives |
| 07/31/2002 | EP1226119A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226115A1 Novel carbamates and ureas |
| 07/31/2002 | EP1225922A1 Selective toxin expression in angiogenic endothelial cells |
| 07/31/2002 | EP1225915A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 07/31/2002 | EP1225911A1 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |
| 07/31/2002 | EP1225900A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/31/2002 | EP1225896A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 07/31/2002 | EP1225884A1 Method for administering a phosphodiesterase 4 inhibitor |
| 07/31/2002 | EP1225882A1 Selective cox-2 inhibitory novel esters from indolealkanols and novel amides from indolealkylamines |
| 07/31/2002 | EP1225866A2 Method and compositions for treating pulmonary diseases |
| 07/31/2002 | EP1035846B1 Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals |
| 07/31/2002 | EP0799059B1 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
| 07/31/2002 | EP0755398B1 Process for the resolution of etodolac using glucamine derivatives |
| 07/31/2002 | EP0744955B1 Cyclic heptapeptide anti-inflammatory agent |
| 07/31/2002 | EP0719267B1 Second messenger cell signaling inhibitors |
| 07/31/2002 | EP0583356B1 A method for treating infectious respiratory diseases |
| 07/31/2002 | CN1361792A Cyclic peptide derivatives as inhibitors of integrin alpha/beta |
| 07/31/2002 | CN1361779A New compounds |
| 07/31/2002 | CN1361775A Novel diphenyl-piperidine derivate |
| 07/31/2002 | CN1361773A Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/31/2002 | CN1361770A Heteroaromatic ring compounds |
| 07/31/2002 | CN1361768A Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 07/31/2002 | CN1361767A 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 07/31/2002 | CN1361763A Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha |
| 07/31/2002 | CN1361760A Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
| 07/31/2002 | CN1361695A Analgesic from snake venom |
| 07/31/2002 | CN1361692A Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts |
| 07/31/2002 | CN1361690A Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |